Takahiro Tsushima

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

Toshihiro Kudo, Yasuo Hamamoto, Ken Kato et al. · The Lancet Oncology · 2017 · 378 citations

Surgical Oncology, Esophageal Cancer, Nivolumab Treatment +8

Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1

Yuko Kitagawa, Ryu Ishihara, Hitoshi Ishikawa et al. · Esophagus · 2023 · 345 citations · Full text

Epidemiology, Part 1, Esophagus +14

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

Kei Muro, Florian Lordick, Takahiro Tsushima et al. · Annals of Oncology · 2018 · 284 citations

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

K. Yamazaki, Michitaka Nagase, H Tamagawa et al. · Annals of Oncology · 2016 · 274 citations · Full text

Gastrointestinal Oncology, Medicine, Pharmacology +9

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

Kei Muro, Eric Van Cutsem, Yukiya Narita et al. · Annals of Oncology · 2018 · 214 citations · Full text